Bioelectronic Medicines, a Rival to Traditional Pharmaceuticals?- An Interview with GSK's Imran Eba
The words Bioelectronic medcine conjour up futuristic images of human-computer integegration that seem more sci-fi than science. GSK however view this as a promising medicinal area as demonstrated by their founding of their Bioloectronics research group and their more recent announcement of a $50m venture capital fund Action Potential Venture Capital which is seeking to invest in this field. Pharma IQ caught up with Imran Eba, partner at Action Potential to discuss this exciting future pharma...
To continue reading this story get free access